Hoffmann-la Roche Inc.

Roche Palo Alto LLC

Maxygen, Inc.

F. Hoffmann-la Roche Ag

Ralf Schumacher

Stefan Seeber

Paul Parren

Jan Van De Winkel

Stephan Fischer

Yvo Graus

Frank Rebers

Phillip A Patten

Torben Lauesgaard Nissen

Klaus-Peter Kuenkele

Sridhar Viswanathan

Anne Vogt

Harald Kropshofer

Olaf Mundigl

Andreas Schaubmar

Michael Weidner

Tanja Ligensa

Erhard Kopetzki

Martine Van Vugt

Hans Koll

Maria Elena Fuentes

Aran Frank Labrijn

Elsie M Eugui

Martin Lanzendoerfer

Dietmar Reusch

Silke Hansen

Joseph Endl

Martine Vriesema-van Vugt

Guy Georges

Joerg Thomas Regula

Stefan Dengl

Michael Brandt

Adelbert Grossmann

Guido Hartmann

Peter Michael Huelsmann

Christian Gassner

Sabine Gruener

Sebastian Breuer

Walter-Gunar Friebe

Kay-Gunnar Stubenrauch

Hubert Kettenberger

Michael Molhoj

Roberto Falkenstein

Joerg Moelleken

Friederike Hesse

Josef Endl

Barbara Weiser

Jan Olaf Stracke

Birgit Masjost

Sebastian Neumann

Suryanarayana Sankuratri

Marc Bedoucha

Sandra Vereecken-Verploegen

Surya Sankuratri

Klaus-peter Kuenkele

Maria Fuentes

Elsie Eugui

Aran Labrijn

Jan Stracke

The invention provides an antibody comprising human IgG1 or IgG3 heavy chain constant domains that are glycosylated with a sugar chain at Asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of NGNA is 1% or less and/or the amount of N-terminal alpha 1,3 galactose is 1% or less, and uses thereof.

Glycosylated antibodies

Herein are reported novel bispecific antibodies that specifically bind to two different antigens selected from the group consisting of human ANG2, human VEGF, human IL-1beta and human PDGF-B.

Bispecific antibodies and methods of use in ophthalmology

Herein are reported humanized anti-IL-1beta antibodies that are humanized variants of the murine anti-IL-1beta antibody H34. A specific humanized antibody comprises (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 25, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 27, and (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 28.

Anti-IL-1beta antibodies

This invention relates to anti-OX40L antibodies and, in particular, to anti-OX40L antibodies and variants thereof that contain a Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from inflammatory diseases.

Anti-OX40L antibodies

The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.

Conjugate of an antibody against CCR5 and an antifusogenic peptide

Method for selecting CHO cell for production of glycosylated antibodies

The instant specification discloses an antibody binding to IL-13R&#x3b1;1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.

Antibodies against IL-13 receptor alpha1 and uses thereof

Antibodies that specifically bind to CCR5 are useful for treating immunosuppressive disease.

Antibodies against CCR5 and uses thereof

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing the antibodies, and uses for the antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.

Antibody selection method against IGF-IR

Antibodies against insulin like growth factor I receptor (IGF-IR), methods for their production, pharmaceutical compositions containing said antibodies, and uses for such antibodies are disclosed. Antibodies against IGF-IR are implicated in antitumor therapy.

Antibodies against insulin-like growth factor I receptor and uses thereof

The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.

Interferon-alpha polypeptides and conjugates

Growing community of inventors

Penzberg, Germany

Ralf Schumacher